50,000 Shares in ChromaDex Co. (NASDAQ:CDXC) Acquired by Sargent Investment Group LLC

Sargent Investment Group LLC purchased a new stake in shares of ChromaDex Co. (NASDAQ:CDXC) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $263,000. Sargent Investment Group LLC owned approximately 0.07% of ChromaDex at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. USA Financial Formulas acquired a new position in shares of ChromaDex in the 4th quarter valued at $25,000. The Manufacturers Life Insurance Company purchased a new stake in ChromaDex during the 2nd quarter valued at about $31,000. FMR LLC acquired a new position in shares of ChromaDex in the third quarter valued at about $55,000. Marshall Wace LLP purchased a new position in shares of ChromaDex in the second quarter worth about $56,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex during the third quarter worth about $61,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Insider Activity

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.64% of the company’s stock.

ChromaDex Trading Up 3.3 %

Shares of NASDAQ:CDXC opened at $5.69 on Thursday. ChromaDex Co. has a 12-month low of $1.46 and a 12-month high of $7.97. The business has a 50 day moving average of $5.95 and a two-hundred day moving average of $4.74. The company has a market capitalization of $434.60 million, a PE ratio of 569.57 and a beta of 2.21.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Roth Mkm raised their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. StockNews.com cut shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 15th. Finally, HC Wainwright upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.